Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

One pill to prevent HIV and pregnancy? new study tests simpler option for women

NCT ID NCT07288190

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a single daily pill that combines HIV prevention (PrEP) and birth control is easier for women to take consistently than taking two separate pills. About 300 women without HIV will try both approaches in a crossover design, and researchers will measure adherence through blood tests. The goal is to see if a simpler regimen improves daily use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
DPP (single pill combining FTC/TDF and ethinyl estradiol/levonorgestrel)
What this could lead to
If it works, this could make it simpler for women to prevent both HIV and pregnancy with just one daily pill.
What could go wrong
This is a small, early-phase study (Phase 2) with only 300 participants, so results may not apply to everyone. It focuses on adherence, not on actual HIV or pregnancy prevention.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 to 39 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 16 through 39 years old (inclusive) at Screening. * Adults must be able and willing to provide informed consent. Adolescents (16- and 17-year-olds) will be consented according to applicable local guidelines, by obtaining participant assent and where applicable parental or guardian permission. * Able and willing to provide adequate locator information. * Able and willing to comply with all study procedures. * Must be post-menarche and pre-menopausal and could potentially become pregnant. * Sexually active, defined as having had penile-vaginal sex within the 3 months before Screening (per self-report) * Negative pregnancy test at Screening and Enrollment. * Does not intend to become pregnant within the next 12 months. * Willing to use COCs for at least 48 weeks as their method of contraception. * HIV negative at Screening and Enrollment. * Willing to use oral PrEP for at least 48 weeks. * Hepatitis B (HBV) surface antigen (HbsAg) negative per blood test at Screening. * Hepatitis C (HCV) negative at Screening. * Normal estimated creatinine clearance (eCrCl) ≥ 60 ml/min per blood test at Screening. Exclusion Criteria: * Intolerance, adverse reaction, or laboratory abnormality associated with PrEP use in the past. * Unable to become pregnant e.g., had a tubal ligation or hysterectomy or otherwise lacks a uterus, or is currently using another form of contraception. * Medically ineligible for combined hormonal contraception and specifically COCs per World Health Organization (WHO) medical eligibility criteria for contraceptive use or similar local medical eligibility guidelines (e.g., Centers for Disease Control and Prevention eligibility criteria). * Medically ineligible for PrEP based on WHO and/or local guidelines. * Using or planning to use another pregnancy prevention product other than oral contraception (condoms are permitted) during the next 48 weeks. * Using or planning to use another HIV prevention product other than condoms during the next 48 weeks. * Any other condition the clinician feels would jeopardize the health and wellbeing of the participant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Eswatini Prevention Center CRS

    Mbabane, Eswatini

  • MU-JHU Research Collaboration (MUJHU CARE LTD) CRS

    Kampala, Uganda

  • Spilhaus CRS

    Harare, Zimbabwe

More trials for these conditions

Other studies related to the condition(s) this trial covers.